Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Five Period Cross-over Study to Evaluate the Efficacy and Safety of Selected Doses and Dose Intervals of GW642444 Administered Via a Novel Dry Powder Inhaler (NDPI) in Subjects greater than or equal to 18 Years of Age With Persistent Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Vilanterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
- 17 May 2011 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
- 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.